BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:uniQure readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies uniQure's drugs run\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06063850-8963@assetmemo.bio
DTSTAMP:20261121T010139Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:AMT-260: Phase 1/2 readout est. (NCT06063850)
DESCRIPTION:AMT-260\, phase 1/2\, Epilepsy.\nStudy: AMT-260 Gene Therapy St
 udy in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy\nEs
 timated primary completion: 30 November 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/amt-260#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06063850
URL:https://assetmemo.bio/drug/amt-260#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06003387-10914@assetmemo.bio
DTSTAMP:20261121T010139Z
DTSTART;VALUE=DATE:20281004
DTEND;VALUE=DATE:20281005
SUMMARY:Hemgenix (etranacogene dezaparvovec): Phase 3 readout est. (NCT0600
 3387)
DESCRIPTION:Hemgenix (etranacogene dezaparvovec)\, phase 3\, Hemophilia B.\
 nStudy: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene The
 rapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus 
 Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)\nEstimated primary comple
 tion: 4 October 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /etranacogene-dezaparvovec#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06003387
URL:https://assetmemo.bio/drug/etranacogene-dezaparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05243017-10915@assetmemo.bio
DTSTAMP:20261121T010139Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ifezuntirgene inilparvovec: Phase 1/2 readout est. (NCT05243017)
DESCRIPTION:Ifezuntirgene inilparvovec\, phase 1/2\, Huntington's Disease.\
 nStudy: Safety and Efficacy of AMT-130 in European Adults With Early Manif
 est Huntington's Disease\nEstimated primary completion: March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ifezuntirgene-inilparvovec#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0524
 3017
URL:https://assetmemo.bio/drug/ifezuntirgene-inilparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04120493-10915@assetmemo.bio
DTSTAMP:20261121T010139Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Ifezuntirgene inilparvovec: Phase 1/2 readout est. (NCT04120493)
DESCRIPTION:Ifezuntirgene inilparvovec\, phase 1/2\, Huntington's Disease.\
 nStudy: Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults Wit
 h Early Manifest Huntington's Disease\nEstimated primary completion: June 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/ifezuntirgene-i
 nilparvovec#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04120493
URL:https://assetmemo.bio/drug/ifezuntirgene-inilparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
